# Myricx Bio

> Myricx Bio is a London-based oncology biotech developing a completely new class of payloads for antibody-drug conjugates (ADCs), built on inhibitors of N-myristoyltransferase (NMT). Spun out of Imperial College London and the Francis Crick Institute, the company aims to give ADCs a fresh way to kill cancer cells that resist today's standard payloads. In July 2024 it closed a £90m ($114m) Series A, one of Europe's largest biotech rounds that year, to push its NMTi-ADC pipeline toward clinical trials.

- **Founded:** 2019
- **Headquarters:** London, United Kingdom
- **Founders:** Edward Tate (Scientific Co-founder, Professor of Chemical Biology (Imperial College London / Francis Crick Institute)), Roberto Solari (Co-founder), Andrew Bell (Co-founder)
- **Team size:** ~35 employees (UK and US)
- **Products:** NMTi-ADC platform, NMT inhibitor payload class, Preclinical oncology pipeline
- **Notable:** Closed £90m ($114m) Series A in July 2024, among the largest European biotech Series A rounds of the year, Spun out of Imperial College London and the Francis Crick Institute on a genuinely novel ADC payload mechanism, Reported complete and durable tumor regressions at well-tolerated doses in solid-tumor models refractory to Topo1i-based ADCs

## Products & services

- **NMTi-ADC platform** — Antibody-drug conjugates carrying N-myristoyltransferase inhibitor payloads, a mechanistically distinct way to kill cancer cells compared with the topoisomerase and tubulin payloads that dominate today's ADCs.
- **NMT inhibitor payload class** — Proprietary small-molecule inhibitors of N-myristoyltransferase, the enzyme that adds a myristoyl lipid tag to proteins essential for cancer cell survival.
- **Preclinical oncology pipeline** — ADC candidates aimed at clinically validated, tumor-associated antigens across multiple solid tumors, including models refractory to Topo1i-based ADCs.

## Achievements

- Closed £90m ($114m) Series A in July 2024, among the largest European biotech Series A rounds of the year
- Spun out of Imperial College London and the Francis Crick Institute on a genuinely novel ADC payload mechanism
- Reported complete and durable tumor regressions at well-tolerated doses in solid-tumor models refractory to Topo1i-based ADCs
- Attracted a marquee investor syndicate including Novo Holdings, Abingworth and Eli Lilly
- Appointed Boston-based Mohit Rawat as CEO in 2025 and expanded leadership across the US and UK

## Latest updates

- **2024-07** — Announced £90m ($114m) Series A co-led by Novo Holdings and Abingworth to advance NMTi-ADCs into clinical development.
- **2025-04** — Expanded leadership team to advance NMTi-ADCs toward clinical development.
- **2025-09** — Appointed Boston-based Mohit Rawat as CEO and expanded the team across the US and UK; Robin Carr moved to CTO.

## Links

- Website: https://myricxbio.com
- LinkedIn: https://www.linkedin.com/company/myricx-pharma-ltd

---

Profile page: https://yespress.io/myricx-bio
Published by YesPress — https://yespress.io
Last updated: 2026-06-07